DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Bothnia retinal dystrophy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBothnia retinal dystrophy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for bothnia retinal dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
retinaldehyde binding protein 1 (RLBP1) — RLBP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet retdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4CJ6 · 1.896 Å · ligand RETINAL (RET). Experimental structure, not a prediction.
What the evidence adds up to
Bothnia retinal dystrophy is not mentioned in any of the provided abstracts. The abstracts cover inherited retinal dystrophies broadly, including retinitis pigmentosa, cone-rod dystrophy, and Bestrophinopathy, but no abstract names Bothnia retinal dystrophy specifically.
One 2015 review states that in approximately 50-60% of patients with nonsyndromic retinal dystrophy, the disease mechanism can now be identified using next-generation sequencing. The same review notes that deep intronic sequencing has uncovered many novel mutations in the ABCA4 gene, and that finding pathogenic alleles in more than one gene is not uncommon. A 2013 German-language review of retinitis pigmentosa states that no established therapy exists, though it lists gene therapy, pharmacological substances, neuroprotection, electrical stimulation, retinal implants, cell transplantation, and optogenetic approaches as areas of ongoing research.
A 2025 case report describes a 65-year-old man with a homozygous USH2A variant (c.10342G>A) who presented with isolated maculopathy, a novel phenotype for USH2A-associated disease, which usually presents as rod-cone dystrophy. A 2019 case report describes a 39-year-old man with rod-cone dystrophy caused by a BEST1 mutation who developed bilateral exudative retinal detachment after creatine monohydrate supplementation; the detachments resolved completely five days after stopping creatine. A 1978 report describes two patients with cone-rod dystrophy and one with dominant retinitis pigmentosa who had perivenous fluorescein leakage in the temporal periphery.
For Bothnia retinal dystrophy specifically, no data on drug repurposing, clinical trials, or treatment outcomes are present in these abstracts. What is missing is any abstract that names the condition, any study of a drug in this population, any trial design, any patient stratification, and any funding directed at this particular dystrophy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Ophthalmology · 2015 · 41 citations · open access
The current status of molecular diagnosis of inherited retinal dystrophies
AbstractPURPOSE OF REVIEW: We are witnessing lightning-fast advances in the molecular diagnosis of inherited retinal dystrophies, mainly due to the widespread use of next-generation sequencing technologies. The purpose of this review is to highlight the breadth of findings from this in-depth testing approach, and to propose changes to our traditional testing and diagnostic paradigms. Lessons learned from modern molecular testing suggest that the previous concept of inherited retinal dystrophies as a group of 'single gene diseases' may require a significant update. RECENT FINDINGS: All of the known retinal dystrophies genes can now be sequenced. In many cases, this nonhypothesis driven testing strategy is uncovering mutations in unsuspected genes, generating data that challenges established concepts of genetic mechanisms and provides insights regarding genes previously thought to be exclusively related to syndromic disease. Recent advances in testing have improved not only the breadth, but also the depth of genetic data. For example, deep intronic sequencing has uncovered many novel intronic mutations/variations in the ABCA4 gene. SUMMARY: Currently, in approximately 50-60% of patients with nonsyndromic retinal dystrophy, the disease mechanism can be identified. The presence of pathogenic alleles in more than one gene is not uncommon. Retinal dystrophy, with relatively defined clinical presentations and a large but limited number of genes involved, is becoming a model for the next-generation study of molecular disease mechanisms.
British Journal of Ophthalmology · 1978 · 19 citations · open access
Retinal dystrophies associated with peripheral retinal vasculopathy.
AbstractA pair of identical twins with cone-rod dystrophy and 1 patient with dominant retinitis pigmentosa are reported who had a peculiar vascular retinopathy characterised by perivenous accumulation of fluorescein in the temporal periphery. Other retinal dystrophies associated with leaking retinal vessels are discussed.
Klinische Monatsblätter für Augenheilkunde · 2013 · 1 citations
Therapeutische Ansätze bei Patienten mit Retinitis pigmentosa
Abstract<b>Hintergrund:</b> Retinitis pigmentosa (RP) bezeichnet einen genetisch und klinisch heterogenen Formenkreis an dystrophischen Netzhauterkrankungen. Im Verlauf der Erkrankung kommt es zu zunehmenden Gesichtsfeldeinschränkungen bis hin zur Erblindung. Bisher ist keine Therapie etabliert. Durch zunehmendes Wissen über die zugrunde liegenden genetischen und pathophysiologischen Veränderungen gibt es eine Reihe von neuen Therapieansätzen, von denen einige hier vorgestellt werden sollen. <b>Methodik:</b> Es wurde eine systematische Literaturrecherche in PubMed zu definierten Stichworten durchgeführt. <b>Ergebnisse:</b> Zu den neuen Therapieansätzen gehören Gentherapie, pharmakologische Substanzen, Neuroprotektion, Elektrostimulation, retinale Implantate, Zelltransplantation und optogenetische Ansätze. <b>Schlussfolgerung:</b> In den letzten Jahren gab es einige Fortschritte in der Erforschung möglicher Therapieansätze bei dystrophischen Netzhauterkrankungen. Die Forschung ist in den einzelnen Bereichen unterschiedlich weit fortgeschritten. Obwohl es nach wie vor keine etablierte Therapie gibt, stehen die Chancen gut, dass in Zukunft zumindest einem Teil der RP-Patienten eine Therapie angeboten werden kann.
Case Reports in Ophthalmology · 2019 · 1 citations · open access
Unique Case of Bilateral Exudative Retinal Detachment following Creatine Supplementation in a Patient with Autosomal Dominant Bestrophinopathy
AbstractWe report a case of bilateral serous retinal detachment in a patient with rod-cone dystrophy caused by mutation of BEST1. This followed creatine monohydrate use as a dietary supplement. A 39-year-old male with rod-cone dystrophy and low hyperopia developed extensive bilateral exudative retinal detachment following creatine monohydrate diet supplementation. Five days after stopping creatine use, the bilateral retinal detachments resolved completely. This may indicate a causative relation of creatine supplementation to development of serous retinal detachment in a susceptible patient with pre-existing retinal dystrophy.
An <i>USH2A</i> variant leading to isolated maculopathy: a novel phenotype
AbstractIntroduction To describe examination and findings in a case of isolated maculopathy with genetic testing revealing an USH2A genotype.Methods/Results A 65-year-old man was found to have slowly worsening central vision in both eyes over several years. Fundus examination showed parafoveal pigmentary changes with an otherwise normal peripheral exam in both eyes. Fundus autofluorescence revealed parafoveal hypofluorescence with surrounding ring like area of hyperfluorescence, with optical coherence tomography (OCT) showing retinal thinning and parafoveal photoreceptor loss. Multifocal electroretinography (ERG) demonstrated diminished central responses, with full field ERG showing normal scotopic response and reduced photopic responses. Genetic testing for retinal dystrophies revealed a homozygous pathogenic variant in USH2A c.10342G>A, p. Glu3448Lys.Discussion USH2A-associated retinal dystrophy usually presents with a rod-cone phenotype. While reports of a cone-rod phenotype have been described, we present the first reported case of isolated maculopathy in USH2A-associated retinal dystrophy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
